Safety and immunogenicity, after nasal application of HIV-1 DNA gagp37 plasmid vaccine in young mice.
Vaccine, September 2008
Jorma Hinkula, Marie Hagbom, Britta Wahren, Ulf Schroder
There is a need for safe and potent adjuvants capable of delivering vaccine candidates over the mucosal barrier, with good capacity to stimulate both mucosal and systemic cell-mediated and humoral immunity. An adjuvant aimed for intranasal delivery should preferably deliver the antigen and minimize the transfer into the close proximity of the central nervous system, thus avoiding damage on the olfactory tissues. Advantages with a mucosal delivery route would be to provide mucosal and systemic immunity, requiring lower vaccine doses then when given parentally. The aim of this study was to study if the N3 adjuvant intranasally administered with HIV DNA plasmids would be transferred into the olfactory tissues and cause local inflammation and tissue damage.
|Readers by professional status||Count||As %|
|Student > Master||2||13%|
|Student > Ph. D. Student||1||7%|
|Professor > Associate Professor||1||7%|
|Readers by discipline||Count||As %|
|Agricultural and Biological Sciences||6||40%|
|Immunology and Microbiology||4||27%|
|Medicine and Dentistry||3||20%|
|Pharmacology, Toxicology and Pharmaceutical Science||1||7%|